Inhibitory effects of HNF4α on migration/maltransformation of hepatic progenitors: HNF4α-overexpressing hepatic progenitors for liver repopulation

Ping Wang 1,2, Min Cong 1, Tianhui Liu 1, Hufeng Xu 1, Lin Wang 1, Guangyong Sun 1, Aiting Yang 1, Dong Zhang 1, Jian Huang 1, Yameng Sun 1, Wenshan Zhao 1, Hong Ma 1, Jidong Jia 1,2* and Hong You 1,2*

Abstract

Background: Although they are expandable in vitro, hepatic progenitors are immature cells and share many immunomarkers with hepatocellular carcinoma, raising potential concerns regarding maltransformation after transplantation. This study investigated the effects of hepatic nuclear factor (HNF) 4α on the proliferation, migration, and maltransformation of hepatic progenitors and determined the feasibility of using these manipulated cells for transplantation.

Methods: The effects of HNF4α on rat hepatic progenitors (i.e., hepatic oval cells) were analyzed by HNF4α overexpression and HNF4α shRNA. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice injured by carbon chloride (CCL4) were then transplanted with control, HNF4α-overexpressing or HNF4α-suppressing hepatic oval cells. Finally, the engraftment of these cells in the recipient liver was analyzed.

Results: Rat hepatic progenitors (i.e., hepatic oval cells) expressed HNF4α, although less than that in hepatocytes. When HNF4α was overexpressed in these cells, the proliferation and migration of hepatic oval cells were reduced; but when HNF4α was suppressed by shRNA, the proliferation and migration, and even anchorage-independent growth, of these cells were accelerated. RNA microarray and gene functional analysis revealed that suppressing HNF4α not only impaired many biosynthesis and metabolism pathways of hepatocytes but also increased pathways for cancer. When transplanted into CCL4-injured NOD/SCID mice, few HNF4α-suppressing hepatic oval cells localized into the liver, while control cells and HNF4α-overexpressing cells engrafted into the liver and differentiated into albumin-positive hepatocytes. Interestingly, the hepatocytes derived from HNF4α-overexpressing cells were less migrative and expressed less c-Myc than the cells derived from control cells.

Conclusion: HNF4α constrains proliferation, migration, and maltransformation of hepatic progenitors, and HNF4α-overexpressing hepatic progenitors serve as an optimal candidate for cell transplantation.

Keywords: Hepatic nuclear factor 4α, Hepatic progenitors, Proliferation, Liver repopulation
**Background**
Orthotopic liver transplantation is the ultimate therapy for patients with end-stage liver diseases but is limited by the shortage of donor organs and the expensive, invasive surgery. Development of cell therapy is critical for treating acute or chronic liver failure and liver-based inherited metabolic disorders [1, 2]. Unfortunately, the availability of high-quality hepatocytes is also limited by organ shortage, and the procedures for isolation, cryopreservation, and cultivation of hepatocytes have detrimental effects on cell viability, metabolic functions, and attachment properties of hepatocytes [3, 4]. Hepatic progenitors with a bipotential signature (i.e. proliferation capacity and differentiation potential) could be long-term expanded in vitro with characteristic stability and genetic integrity [5–7], thus providing a renewable cell source for transplantation. Yet the activation of hepatic progenitors precedes most of the carcinogenic process in chemically induced hepatocellular carcinoma (HCC) animal models, and correlates with the degree of inflammation and stage of fibrosis in human chronic liver diseases [8–11], raising concerns of carcinogenesis and complicating the usage of hepatic progenitors for cell transplantation. Therefore, it is a critical issue to constrain proliferation and prevent maltransformation of hepatic stem/progenitor cells to optimize their clinical usage.

Among the liver-enriched transcription factors we have known, hepatic nuclear factor (HNF) 4α, which acts as a master regulator of liver morphogenesis and hepatocyte differentiation, has anti-proliferation and tumor-suppression functions in the liver [12–15]. Therefore, in the present study we investigated the effect of HNF4α on rat hepatic progenitor cells (also called hepatic oval cells) and determined the feasibility of using these HNF4α manipulated cells for transplantation in carbon chloride (CCL4)-injured nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice.

**Methods**

**Detection of HNF4α expression in hepatic progenitors**
Hepatic oval cells were isolated by collagenase perfusion and discontinuous gradient centrifugation from rats fed with a choline-deficient diet supplemented with ethionine [7]. The immunophenotype of hepatic oval cells was analyzed by flow cytometry after immunofluorescence staining as described in Additional file 1: Methods. The expression of HNF4α in hepatic oval cells was detected by real-time PCR (RT-PCR) using the isolated rat hepatocytes, cholangiocytes, hepatic stellate cells, endothelial cells, and hepatic oval cells as described in Additional file 1: Methods.

**Manipulation of hepatic oval cells by overexpressing or suppressing HNF4α**
HNF4α-overexpression plasmids were constructed by amplifying the HNF4α gene from the rat genome DNA by PCR with the forward primer 5′-ataagcttgacattgga-catgcgctacta-3′ (HindIII site underlined) and the reverse primer 5′-atgtacctatggcctcgctgg-3′ (KpnI site underlined). This 1401-bp rat HNF4α gene was inserted into the HindIII/KpnI sites of EGFP-N1 vector (BD Biosciences Clontech, Palo Alto, CA, USA) and confirmed by DNA sequencing, forming a recombinant HNF4α plasmid. The HNF4α plasmids were transfected to hepatic oval cells by Lipofectamin 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Two days post transfection, flow cytometry was used for sorting out EGFP-positive cells according to the method described previously [16], and the sorted cells were cultured in the presence of G418 (Invitrogen) antibiotic selection at 200 µg/ml for 18 days. HNF4α shRNA and negative control, noneffective shRNA were obtained from Santa Cruz (Dallas, TX, USA) and transfected to hepatic oval cells by Lipofectamin 3000 (Invitrogen) according to the manufacturer’s instructions. Two days post transfection, the cells were selected by Puromycin (Santa Cruz) antibiotic selection at 1 µg/ml for 18 days.

**Proliferation and migration of hepatic oval cells after HNF4α overexpression or suppression**
Proliferation capacity of hepatic oval cells at 4 days post transfection of the EGFP vector, HNF4α plasmids, non-effective shRNA, or HNF4α shRNA was analyzed by RT-PCR and/or western blot analysis for proliferating cell nuclear antigen (PCNA) and cyclin D1 (CCND1) as described in Additional file 1: Methods. Migration capacity was analyzed by scratch wound healing assay and the anchor-independent growth capacity was detected with soft agar according to the methods described in Additional file 1: Methods.

**Gene expression of HNF4α-overexpressing or HNF4α-suppressing hepatic oval cells**
Gene expression profiling of hepatic oval cells (5 x 10⁶) at 4 days post transfection of EGFP vector, HNF4α plasmids, or HNF4α shRNA was analyzed according to the methods described previously [17].

**Transplantation of HNF4α-overexpressing or HNF4α-suppressing hepatic oval cells to CCl4-injured NOD/SCID mice**
Six-week-old female NOD/SCID mice (body weight (B.W.) around 22 g) were obtained from Beijing HFK Bioscience Co. (Beijing, China) and housed under 12/12-hour light/dark cycles with free access to standard pelleted chow and water. The Animal Care and Use Committees at Beijing Friendship Hospital, Capital Medical University, approved the protocols of these animal experiments. Liver injury was induced by intraperitoneal injection of CCl₄.
(Sigma-Aldrich, St Louis, MO, USA) in olive oil (1:9, v/v; Sigma-Aldrich) at a dose of 0.1 ml/20 g B.W. twice per week for 2 weeks. Two days post final CCl₄ injection, mice received phosphate-buffered saline (PBS, n = 5), 1 x 10⁶ EGFP-vector (n = 5), HNF4α-plasmid (n = 6) or HNF4α-shRNA (n = 3) transfected hepatic oval cells at 4 days post transfection by tail vein injection. The mice were sacrificed at 2 weeks after cell transplantation to collect tissue. Engraftment of cells was verified by double immunofluorescence of ALB and/or GFP.

Detection of proliferation, migration, and transformation markers in the engrafting cells
Liver tissues with detectable engrafting EGFP-vector or HNF4α-plasmid transfected hepatic oval cells were double-immunostained with ALB and Ki-67 for proliferation analysis, or ALB and MMP2 for migration analysis, or ALB and c-Myc for transformation analysis.

Statistical analysis
All cell counts were performed on blind-coded samples. Both the total cell numbers (at least 500) based upon DAPI-positive nuclei and the numbers of cells based upon immunoreaction to different markers within the same field were counted from three independent experiments. Data are expressed as the mean ± SD. All comparisons for the study were performed by Student t test with SPSS version 16.0. P < 0.05 was considered statistically significant.

Results
Hepatic oval cells express HNF4α, yet at lower levels than hepatocytes
In order to investigate HNF4α expression in hepatic progenitors and further analyze the effects of HNF4α on hepatic progenitors, rat hepatic progenitors (also called hepatic oval cells) were successfully isolated and their progenitor phenotype was confirmed by 83.9%, 96.9%, 98.1%.

![Fig. 1 Hepatic progenitors expressed liver-enriched transcription factor HNF4α.](image-url)
and 98.1% positive for markers of hepatic oval cells OV6, BD1, and Dlk (Fig. 1a). These cells are also double positive for the markers of hepatic stem/progenitor cells; that is, epithelial cell adhesion molecule (EpCAM) and HNF-1β or α-fetoprotein (AFP) and SRY-related HMG box transcription factor 9 (Sox9) (Fig. 1b). RT-PCR analysis showed that cholangiocytes, hepatic stellate cells, and endothelial cells did not express HNF4α, but hepatic oval cells and hepatocytes expressed HNF4α, although the expression of HNF4α in hepatic oval cells was at lower levels than that in hepatocytes (Fig. 1c).

Fig. 2 HNF4α overexpression suppressed the proliferation and migration of hepatic oval cells. a Recombinant HNF4α-overexpression plasmid and empty EGFP-N1 vector. b Forty-eight hours post transfection of HNF4α or EGFP-N1 plasmids, EGFP fluorescence was detected in some hepatic oval cells. c HNF4α-overexpressing hepatic oval cells isolated by flow cytometry. d RT-PCR data revealed that HNF4α-overexpressing hepatic oval cells showed more transcription of HNF4α and ALB, yet less transcription of CCND1 and PCNA. e Western blot analysis confirmed that HNF4α-overexpressing hepatic oval cells expressed more HNF4α and ALB, yet less PCNA. f Wound closure was photographed and evaluated at 0 and 24 hours post scratching of HNF4α-overexpressing cells and EGFP-N1 control cells. Overexpression of HNF4α reduced the speed of wound closure when compared to EGFP-N1 control cells. ALB albumin, CCND1 cyclin D1, HNF hepatic nuclear factor, PCNA proliferating cell nuclear antigen (Color figure online)
**Overexpression of HNF4α reduces the proliferation and migration of hepatic oval cells**

HNF4α-overexpression plasmids were constructed (Fig. 2a) and transfected into hepatic oval cells as revealed by green fluorescence at 2 days post transfection (Fig. 2b). The cells with green fluorescence were then sorted out by flow cytometry (Fig. 2c) and cultured in the presence of G418 for 18 days. The overexpression of HNF4α was confirmed by real-time PCR and western blot analysis at 4, 8, 12, 16, and 20 days post transfection (Fig. 2d, e). HNF4α overexpression increased the transcription and expression of ALB, but reduced the expression of PCNA and cyclin D1, when compared to the EGFP-vector transfected control cells at 4, 12, 16, and 20 days post transfection (Fig. 2d, e)—although there is a slight variation for the transcription of PCNA and cyclin D1 under the selection of G418 at 8 days post transfection, which may be interfered with by the dying unsuccessfully transfected cells. Moreover, HNF4α overexpression resulted in a delay in wound closure induced by scratching when compared to EGFP-N1 transfected cells (Fig. 2f).

**Inhibition of HNF4α enhances the proliferation and migration of hepatic oval cells**

Compared with noneffective shRNA transfected hepatic oval cells, HNF4α-shRNA transfected cells showed obvious morphology changes with more cell filaments and reduced nuclear to cytoplasm ratio (Fig. 3a). The expression...
of HNF4α was reduced at 4, 8, 12, 16, and 20 days post transfection as revealed by RT-PCR and western blot analysis (Fig. 3b, c). Inhibition of HNF4α increased the expression of PCNA and cyclin D1, but reduced the expression of ALB in shHNF4α transfected cells as compared to non-effective shRNA transfected cells at 4, 12, 16, and 20 days post transfection (Fig. 3b, c), and there was also a slight variation for the transcription of ALB, PCNA, and cyclin D1 under the selection of puromycin at 8 days post transfection. Furthermore, suppressing HNF4α increased the wound closure induced by scratching when compared to non-effective shRNA transfected cells (Fig. 3d). In addition, suppression of HNF4α caused hepatic oval cells to proliferate in soft agar although much slower than positive control HepG2 cells, while there was no proliferating signature of the noneffective shRNA transfected cells (Fig. 3e).

**HNF4α contributes to the hepatocyte function pathways and restricts the maltransformation pathway of hepatic progenitors**

To explore the gene expression variations of HNF4α on hepatic oval cells, whole transcript expression analysis was performed on cells transfected with HNF4α plasmids or HNF4α shRNA by comparing them to EGFP-vector transfected cells. Because we did not find much difference between EGFP-vector transfected cells and noneffective shRNA transfected cells from the previous experiments, only EGFP-vector transfected cells were used as control cells in the transcript-expression analysis and transplantation experiments. After raw data normalization and probe set summary, the expression values of 30,430 transcript clusters were analyzed for differential expression between cells transfected with HN4α plasmids versus HNF4α shRNA versus EGFP-vector plasmids. Intensities of the top 200 differentially expressed genes were subjected to agglomerative hierarchical clustering (AHC) and the results displayed as a heat map (Fig. 4a). The dendrogram showed that the relative gene expression values distinguish the HNF4α-overexpressing cells from the HNF4α-suppressing cells and the control cells. Signal pathways controlled by HNF4α were analyzed by the array data of the HNF4α-overexpressing cells and HNF4α-suppressing cells on the Database for Annotation, Visualization and Integrated Discovery. Among the top 10 enrichment scores, suppressing HNF4α cells greatly reduced the pathways of biosynthesis (steroid, terpenoid backbone, aldosterone, unsaturated fatty acids) and biometabolism (fatty acid, carbon), while increasing pathways in cancer, compared to HNF4α-overexpressing cells (Fig. 4b).

**HNF4α is essential for hepatic oval cells to engraft and reconstitute CCl4-injured NOD/SCID mouse liver**

Hepatic oval cells, which were obtained from rat and transfected with EGFP vector, HNF4α plasmids, or
HNF4\(\alpha\) shRNA, were transplanted into CCL\(_4\)-injured NOD/SCID mice by tail vein injection (scheme of experimental design shown in Fig. 5a). Expression of rat-specific ALB and/or EGFP in the mice liver could localize the cells derived from the transplanted cells. As shown in Fig. 5b, few rat ALB-positive cells could be detected in the mouse liver after transplanting HNF4\(\alpha\)-suppressing hepatic oval cells to CCL\(_4\)-injured NOD/SCID mice \((n = 3)\), which was similar to CCL\(_4\)-injured mouse liver injected with PBS instead of cells \((n = 5)\). However, rat ALB and EGFP double-positive hepatocytes could be detected in the mice transplanted with EGFP-vector transfected control (four of five mice, \(n = 5\)) or HNF4\(\alpha\)-overexpressing (two of six mice, \(n = 6\)) hepatic oval cells (Fig. 5b), indicating that suppression of HNF4\(\alpha\) resulted in defects for hepatic progenitors engrafting into the liver parenchyma (i.e., HNF4\(\alpha\) is a pivotal transcription factor for the engraftment of hepatic progenitors).

HNF4\(\alpha\) restricts migration and reduces c-Myc expression in the engrafting hepatic oval cells

For the cells that engrafted into the liver parenchyma, the hepatocytes derived from HNF4\(\alpha\)-overexpressing hepatic progenitors settled around the portal vein (identified by the bile duct cells around it), in contrast to the hepatocytes derived from control hepatic oval cells that migrated distally from the portal vein and distributed in the lobule (Fig. 5b). Double immunofluorescence staining of ALB and Ki-67 or ALB and MMP2 revealed that the engrafting cells, derived either from HNF4\(\alpha\)-overexpressing hepatic oval cells or from EGFP-vector transfected controls, did not express the proliferation marker Ki-67 (Fig. 6a), but the engrafting cells from both groups expressed MMP2 (Fig. 6b). Furthermore, some of the engrafting cells derived from EGFP-vector transfected control cells were intensively positive for c-Myc, while c-Myc expression was weak in those cells derived from HNF4\(\alpha\)-overexpressing cells (Fig. 6c). It is noteworthy that most of the c-Myc-positive cells were around the portal vein, while the cells which migrated into the lobule no longer expressed c-Myc (Fig. 6c). Therefore, these data suggest that the HNF4\(\alpha\) expression level determined different reconstitution models of hepatic progenitors (Fig. 7), and although overexpression of HNF4\(\alpha\) reduced the engraft efficiency of hepatic oval cells, overexpression of HNF4\(\alpha\) restricted the migration and reduced the expression of transformation marker in hepatic oval cells.

**Fig. 5** HNF4\(\alpha\) was a key transcription factor for hepatic oval cells engrafting and repopulating CCL\(_4\)-injured NOD/SCID mouse liver. **a** Experimental design of transplanting control, HNF4\(\alpha\)-overexpressing, or HNF4\(\alpha\)-suppressing rat hepatic oval cells into CCL\(_4\)-injured NOD/SCID mice by tail vein injection. **b** Immunofluorescence data revealed that few ALB-positive cells could be detected in HNF4\(\alpha\)-suppressing hepatic oval cell-transplanted mice, while ALB and GFP double-positive cells could be detected in the mice transplanted with control and HNF4\(\alpha\)-overexpressing hepatic oval cells. Hepatocytes derived from HNF4\(\alpha\)-overexpressing oval cells were located around the portal vein, while hepatocytes derived from control oval cells migrated into the recipient liver parenchyma. ALB albumin, CCL\(_4\) carbon chloride, HNF hepatic nuclear factor (Color figure online)
Discussion
In this study, we find that HNF4α constrains proliferation/migration capacity, thus reducing the maltransformation possibility of hepatic progenitors. Furthermore, HNF4α is an essential transcription factor for localizing hepatic progenitors to the injured liver, and different HNF4α expressing levels result in different liver reconstitution models of the transplanted hepatic progenitors, suggesting the feasibility of using HNF4α-manipulated hepatic stem/progenitor cells for transplantation.
Overexpression of HNF4α reduces proliferation/migration capacity of hepatic progenitors, while suppression of HNF4α results in maltransformation signatures. Our results are in agreement with the data that HNF4α suppresses hepatocyte proliferation [13], and are also consistent with the data reporting that inhibition and/or deletion of HNF4α results in promoting hepatocyte proliferation and hepatocellular carcinogenesis, confirming the anti-proliferation and anti-tumorigenesis effects of HNF4α [14, 18, 19]. Thus, manipulation expandable hepatic progenitors through HNF4α overexpression may relieve the concern of maltransformation and provide a sufficient supply of cells for transplantation.

It has been demonstrated that transplantation of hepatic progenitors, which lack sufficient maturity, could reconstitute liver tissue [20–22]. Our study steps further to overexpress HNF4α in hepatic progenitors to restrict proliferation/migration and relieve maltransformation concerns. Although both unmanipulated and HNF4α-overexpressing hepatic progenitors could repopulate the liver parenchyma with ALB-positive hepatocytes, transplantation of HNF4α-overexpressing cells is superior to that of unmanipulated cells in that hepatocytes derived from HNF4α-overexpressing progenitors are less migratory and settle around the portal vein, while the hepatocytes derived from unmanipulated cells migrate into the liver lobe. The reconstitution model of HNF4α-overexpressing cells is similar to the hepatocyte islands or foci derived from mouse or human hepatic stem/progenitor cells, which have been organoid cultivated to induce hepatocyte differentiation, after splenic transplantation into FAH<sup>−/−</sup> mice or Balb/c nude mice treated with CCl<sub>4</sub>-retotsine [5, 6]. Considering the migration marker MMP2 is not differentially expressed in the engrafting cells derived from hepatic progenitor cells and HNF4α-overexpressing progenitor cells, there might be some other factors that restrict the migration of HNF4α-overexpressing cells. It has been reported that the larger the cells are, the closer these cells will be to the portal areas after transplantation [23]. The enlarged cell size post HNF4α overexpression may therefore contribute to the different reconstitute models between hepatic progenitors and HNF4α-overexpressing progenitors. Our data reveal that the transformation marker c-Myc is more extensively expressed in the engrafting cells derived from hepatic progenitors around the portal vein than those cells derived from HNF4α-overexpressing cells, although most of the cells derived from HNF4α-overexpressing cells are around the portal vein. Considering c-Myc as an essential transformation marker of aggressive carcinoma cells, the less migratory hepatocytes derived from HNF4α-overexpressing progenitors in vivo reduce the maltransformation possibility of the transplanted cells and provide expandable cells for transplantation.

Of note is that the engraft efficiency of HNF4α-overexpressing hepatic progenitors is not as good as that of unmanipulated hepatic progenitors. Similar results from Zagoura et al. [24] revealed that hepatocyte-like cells fail to engraft into CCl<sub>4</sub>-injured NOD/SCID mice, while hepatic progenitor-like cells incorporate into these mice with therapeutic effects. Yovchev et al. [25] also found that DPPIV<sup>+</sup> mature hepatocytes reconstitute DPPIV<sup>−</sup> liver mass to a lesser extent than stem/progenitor cells derived from DPPIV<sup>+</sup> rat fetal liver. Therefore, it is no surprise to find the lower engraft efficiency for HNF4α-overexpressing hepatic progenitors than unmanipulated progenitors.

Fig. 7 Proposed engraftment and reconstitution models of hepatic progenitors with different HNF4α expression levels. HNF hepatic nuclear factor (Color figure online)
because HNF4α directs them to differentiation toward hepatocytes, although they are not as mature as hepatocytes. Procedures for improving engraft efficiency of HNF4α-overexpressing hepatic progenitors still need further exploration, including the application of vaso- dilators to help these manipulated cells penetrate through the endothelial barriers.

Conclusions
HNF4α is an essential transcription factor for restricting the proliferation/migration/maltransformation of hepatic progenitors and controlling their liver repopulation behaviors. HNF4α-overexpressing hepatic progenitors may serve as an alternative cell source for transplantation to treat liver diseases.

Additional file

Additional file 1: Presents supplemental materials and methods. (DOCX 19 kb)

Abbreviations
ALB: Albumin; CCl4: Carbon chloride; CCND1: Cyclin D1; EpCAM: Epithelial cell adhesion molecule; HNF4α: Hepatic nuclear factor 4α; NOD/SCID: Nonobese diabetic/severe combined immunodeficiency; PCNA: Proliferating cell nuclear antigen

Acknowledgements
The authors thank the Clinical Data and Biobank Resource of Beijing Friendship Hospital for storing liver samples.

Funding
This study was supported by grants from the National Natural Science Foundation of China (81570548 and 81270519), the Beijing Municipal Natural Science Foundation (7132095), and the Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges under Beijing Municipality (IDHT20150502).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
PW, HY, and JJ designed the experiments and analyzed the data. PW, MC, TL, LL, HX, LW, GS, AY, YS, and WZ performed the experiments. DZ, JH, and HM contributed to reagents/materials/analysis tools and interpretation of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The animal experiments were approved by the Animal Care and Use Committees at Beijing Friendship Hospital, Capital Medical University (No. 16-2003).

Competing interests
The authors declared that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis & National Clinical Research Center of Digestive Diseases, Beijing 100050, China.
2 Municipal Laboratory for Liver Protection and Regulation of Regeneration, Capital Medical University, Beijing 100069, China.

Received: 20 March 2017 Revised: 22 June 2017 Accepted: 10 July 2017 Published online: 14 August 2017

References
1. Forbes SJ, Gupta S, Dhawan A. Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol. 2015;62(1 Suppl):S157–69.
2. Gantz T, Sharma AD, Ott M. Concise review: Cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments. Stem Cells. 2015;33(4):1055–62.
3. Seppen J, Filali EE, Elferink RO. Small animal models of hepatocyte transplantation. Methods Mol Biol. 2009;481:75–82.
4. Terry C, Hughes RD, Mitry RR, Lehec SC, Dhawan A. Cryopreservation-induced nonattachment of human hepatocytes: role of adhesion molecules. Cell Transplant. 2007;16(6):639–47.
5. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, et al. Long-term culture of genome-stable bipotential stem cells from adult human liver. Cell. 2015;160(1–2):299–312.
6. Huch M, Dorrell C, Buj SF, van Es JH, Li VS, van de Wetering M, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494(7436):247–50.
7. Wang P, Cong M, Liu TH, Yang AT, Cong R, Wu P, et al. Primary isolated hepatic oval cells maintain progenitor cell phenotypes after two-year prolonged cultivation. J Hepatol. 2010;53(5):863–71.
8. Allison MR, Islam S, Sinn S. Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. J Pathol. 2009;217(2):282–98.
9. Williams MJ, Clouston AD, Forbes SJ. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology. 2014;146(2):349–56.
10. Lowes KN, Brennan BA, Yeoh GC, Olynky J. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol. 1999;154(2):537–41.
11. Rokasim T, Yang SQ, Koteish A, Dunne A, DeVos R, Huang X, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol. 2003;163(4):1301–11.
12. Parviz F, Matullo C, Garrison WD, Savastini L, Adamson JW, Ning G, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003;34(3):292–6.
13. Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012;287(10):7345–56.
14. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110–4.
15. Waleyse C, Apte U. Role of hepatocyte nuclear factor 4α (HNF4α) in cell proliferation and cancer. Gene Expr. 2015;16(3):101–8.
16. Wang P, Zhang H, Li W, Zhao Y, An W. Promoter-defined isolation and identification of hepatic progenitor cells from the human fetal liver. Histochem Cell Biol. 2008;130(2):175–85.
17. Wang P, Cong M, Liu T, Yang A, Sun G, Zhang D, et al. The characteristics variation of hepatic progenitors after TGF-β1-induced transition and EGF-induced reversion. Stem Cells Int. 2016;2016:630485.
18. Waleyse C, Edwards G, Borude P, Guenwardena S, O’Neill M, Yoo B, et al. Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 2013;57(6):2480–90.
19. Huck I, Manley Jr MW, Apte U. Role of hepatocyte nuclear factor 4 alpha (HNF4α) in hepatocyte regeneration. FASEB J. 2016;30:242.5.
20. Español-Suñer R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, et al. Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in mice. Gastroenterology. 2012;143(6):1564–75.e7.
21. Rodrigo-Torres D, Affo S, Coll M, Morales-Ibanez O, Millan C, Blaya D, et al. The biliary epithelium gives rise to liver progenitor cells. Hepatology. 2014; 60(4):1367–77.
22. Lu WY, Bird TG, Boulter L, Tsuchiya A, Cole AM, Hay T, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. Nat Cell Biol. 2015;17(8):971–83.
23. Rajavanshi P, Kerr A, Bhargava KK, Burk RD, Gupta S. Studies of liver repopulation using the dipetidyl peptidase N-deficient rat and other
rodent recipients: cell size and structure relationships regulate capacity for increased transplanted hepatocyte mass in the liver lobule. Hepatology. 1996;23(3):482–96.

24. Zagoura DS, Roubelakis MG, Bitsika V, Trohatou O, Pappa KI, Kapelouzou A, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut. 2012;61(6):894–906.

25. Yovchev MI, Xue Y, Shafritz DA, Locker J, Oertel M. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology. 2014;59(1):284–95.